Engineering of NK activating receptor ligands enhances immune compatibility of MHC-I−/− iPSC-derived β cells for cell therapy of type 1 diabetes

Raniero Chimienti, Lorenzo Piemonti, Fabio Manenti et al.|Cytotherapy|2020

Cited by 2